15 Best Growth Stocks to Invest in for the Next 5 Years

Page 6 of 13

8. Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Upside potential as of June 24, 2025: 161.07%

Analysts at H.C. Wainwright have reaffirmed their $10.00 price target on Aquestive Therapeutics, Inc. (NASDAQ:AQST) while maintaining a Buy rating. This positive outlook follows the approval of a New Drug Application for Anaphylm by the U.S. Food and Drug Administration.

Earlier last week, Anaphylm, a leading non-device-based epinephrine product candidate for immediate treatment of severe allergic reactions, was accepted for review. The FDA has set a Prescription Drug User Fee Act date for January 31, 2026. Wallet portability, rapid onset, and high patient preference are among the many benefits provided by the leading drug that is well-positioned to secure a market share of $2 billion.

According to the management, Anaphylm has shown clinical outcomes on par with autoinjectors like EpiPen and Auvi-Q. Its sublingual administration is what sets it apart from nasal spray-based epinephrine products.

Aquestive Therapeutics, Inc. (NASDAQ:AQST), headquartered in New Jersey, is a pharmaceutical company that develops and markets solutions to address unmet medical needs. Incorporated in 2004, the company uses innovative drug delivery technologies like PharmFilm and Adrenaverse.

Page 6 of 13